Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Background/AimsData on the efficacy and safety of the adalimumab biosimilar Exemptia are limited.MethodsPatients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimilars,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of Intestinal Diseases
2018-01-01
|
| Series: | Intestinal Research |
| Subjects: | |
| Online Access: | http://www.irjournal.org/upload/pdf/ir-16-83.pdf |